证券代码:600829 证券简称:人民同泰 编号:临 2024-010 哈药集团人民同泰医药股份有限公司 关于2023年度暨2024年第一季度业绩暨现金分红说明会 召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 哈药集团人民同泰医药股份有限公司（以下简称"公司"）于 2024 年 5 月 7 日披露了《关于召开 2023 年度暨 2024 年第一季度业绩暨现金分红说 明会的公告》（公告编号：临 2024-009）。公司于 2024 年 5 月 15 日召开了 2023 年度暨 2024 年第一季度业绩暨现金分红说明会，就公司经营情况及利 润分配等方面与投资者进行交流和沟通。现将有关事项公告如下： 一、本次说明会召开情况 在本次说明会上，公司就经营情况和业务开展、利润分配等方面，对 投资者普遍关心的问题给予了答复，相关问题及回复整理如下： 问题一：公司营收业绩稳定，是否考虑提高分红比例？ 回答：尊敬的投资者您好，公司董事会高度重视投资者回报，利润分 配方案根据相关法律法规和《公司章程》相关规定，结合公司所处行业特 ...

证券代码：600829 证券简称：人民同泰 编号：临 2024-009 2、会议召开地点：全景网"投资者关系互动平台"（http://ir.p5w.net）。 3、会议召开方式：网络远程方式。 三、参加人员 哈药集团人民同泰医药股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 哈药集团人民同泰医药股份有限公司（以下简称"公司"）分别于 2024 年 3 月 28 日披露了《2023 年年度报告》及《2023 年度利润分配预案的公告》，2024 年 4 月 20 日披露了《2024 年第一季度报告》。为进一步加强与投资者的互动交 流，便于广大投资者更全面深入了解公司经营业绩和利润分配等具体情况，公司 计划于 2024 年 5 月 15 日(星期三) 15:00-16:00 召开 2023 年度暨 2024 年第一 季度业绩暨现金分红说明会。公司将与投资者进行网上交流，在信息披露允许的 范围内就投资者普遍关注的 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 2,598,035,321.93, representing a year-on-year decrease of 2.09%[14] - Net profit attributable to shareholders increased by 9.12% year-on-year, amounting to CNY 78,333,942.38[14] - The net profit after deducting non-recurring gains and losses was CNY 77,135,172.21, reflecting an 8.80% increase compared to the previous year[14] - Total operating revenue for Q1 2024 was CNY 2,598,035,321.93, a decrease of 2.08% compared to CNY 2,653,397,225.81 in Q4 2023[25] - Net profit for Q1 2024 reached CNY 78,333,942.38, representing an increase of 8.88% from CNY 72,129,935.24 in Q4 2023[25] - The company reported a gross profit margin of approximately 4.05% for Q1 2024, compared to 3.89% in Q4 2023[25] - Net profit attributable to shareholders of the parent company increased from RMB 71.79 million to RMB 78.33 million, representing a growth of approximately 9.5%[47] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,353,029,675.77, a decrease of 0.99% from the end of the previous year[15] - Total current assets slightly decreased to CNY 6,864,269,329.03 from CNY 6,924,629,944.87, a reduction of 0.87%[22] - Total liabilities decreased to CNY 4,523,320,268.93 from CNY 4,675,089,264.47, a decline of 3.25%[22] - Accounts receivable increased to CNY 4,367,694,197.59 from CNY 4,175,242,517.14, reflecting a growth of 4.6%[22] - Cash and cash equivalents decreased to CNY 1,054,337,369.23 from CNY 1,314,347,180.73, a decline of 19.8%[22] - Short-term borrowings increased from RMB 962.08 million to RMB 1,112.08 million[42] - Accounts payable decreased from RMB 1,600.07 million to RMB 1,400.50 million[42] Cash Flow - Cash flow from operating activities was negative at CNY -336,296,768.32, indicating a significant cash outflow[14] - The cash inflow from operating activities totaled CNY 2,380,906,068.67, a decrease of 6.1% compared to CNY 2,535,272,930.90 in the previous period[50] - The net cash outflow from operating activities was CNY -336,296,768.32, worsening from CNY -38,881,437.25 in the previous period[50] - The cash inflow from financing activities was CNY 300,000,000.00, down from CNY 360,000,000.00 in the previous period, representing a decrease of 16.7%[51] - The net cash flow from financing activities improved to CNY 130,771,358.30, compared to CNY 68,167,091.77 in the previous period, an increase of 91.8%[51] Operational Efficiency - The weighted average return on net assets was 2.81%, a decrease of 0.06 percentage points[14] - The company reduced financing costs, leading to a decrease in financial expenses by CNY 6,411,200, or 4.76% year-on-year[6] - Employee compensation decreased by RMB 15.86 million compared to the beginning of the period, mainly due to the payment of last year's performance bonuses[38] - Lease liabilities decreased by RMB 12.26 million compared to the beginning of the period, primarily due to payments made as per lease contract expiration[38] - Tax and additional charges increased by RMB 3.55 million compared to the same period last year, mainly due to an increase in related taxes[38] - Other income increased by RMB 0.48 million compared to the same period last year, primarily due to receiving stability subsidies[38] Strategic Focus - The company aims to enhance its wholesale business by optimizing product variety and strengthening customer management, targeting a 1.02% year-on-year revenue growth[35] - The company is focusing on expanding its retail business by leveraging brand advantages and improving product structure[35] - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated in the earnings call[55] - The company has not reported any significant mergers or acquisitions in the current quarter[55] Research and Development - The company incurred research and development expenses, although specific figures were not disclosed in the provided data[53]

Financial Performance - The net profit attributable to shareholders for 2023 was CNY 292,161,807.26, with the parent company achieving a net profit of CNY 510,783.26[4] - The proposed cash dividend is CNY 1.44 per 10 shares, totaling CNY 83,503,957.97, which represents 28.58% of the net profit for the year[4] - The total distributable profit for shareholders for the year is CNY 1,001,442,088.40, including retained earnings from the previous year[4] - The company's operating revenue for 2023 reached CNY 10,389,980,124.13, an increase of 7.77% compared to 2022[24] - Net profit attributable to shareholders was CNY 292,161,807.26, reflecting a year-on-year growth of 10.47%[25] - The basic earnings per share for 2023 was CNY 0.5038, up 10.46% from the previous year[22] - The net cash flow from operating activities was CNY 332,985,565.90, an increase of 8.35% year-on-year[25] - The total assets of the company at the end of 2023 were CNY 7,426,464,728.93, representing a 5.21% increase from 2022[21] - The gross margin improved due to steady sales growth and effective cost management, leading to a decrease in management expenses[25] Revenue Breakdown - The wholesale business accounted for 83.27% of total revenue, with sales revenue of CNY 865,150.48 million, a year-on-year increase of 7.26%[24] - Retail business revenue was CNY 160,058.32 million, growing by 10.35% year-on-year, supported by brand strength and improved product structure[24] - The wholesale segment generated revenue of CNY 865,150.48 million, reflecting a growth of 7.26% year-on-year[35] - The retail segment's revenue was CNY 160,058.32 million, with a year-on-year growth of 10.35%[37] - The pharmaceutical business generated revenue of CNY 10,252,088,002.76, with a growth rate of 7.73% compared to the previous year, accounting for 99.06% of total operating revenue[81] Operational Efficiency - The company has confirmed no non-operational fund occupation by controlling shareholders or related parties[6] - The audit report issued by the accounting firm was a standard unqualified opinion[7] - The company has implemented a centralized supply chain system for its retail operations, optimizing logistics and reducing operational costs[65] - The company has completed a commercial distribution integration transformation, improving overall operational efficiency and collaboration between wholesale and retail sectors[70] - The company operates a modern logistics distribution center that ensures cold chain transportation for temperature-sensitive products, maintaining drug quality[64] Market Position and Strategy - The company is focusing on enhancing its product offerings and optimizing market channels to drive future growth[32] - The company is actively enhancing its brand and service quality through strategic partnerships and market expansion initiatives[36] - The company has expanded its distribution network beyond Heilongjiang to Jilin and Inner Mongolia, enhancing its market reach[64] - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers, ensuring a stable supply chain[61][63] - The company aims to expand its market coverage and improve service levels by enhancing product capabilities and optimizing its marketing network in response to intensified market competition[124] Employee and Management - The total number of employees at the parent company and major subsidiaries is 2,960, with 2,830 employees in major subsidiaries and 130 in the parent company[170][171] - The company has a strong management team with diverse backgrounds in finance, law, and pharmaceuticals[148] - The company has implemented a performance-based salary system for its directors and senior management, linking compensation to financial results and management goals[154] - A total of 150 training programs were conducted to improve the professional capabilities of employees, particularly in the pharmaceutical services sector[173] - The company emphasizes the importance of employee welfare and development, providing training and health checks for staff[192] Governance and Compliance - The company has established a compliance management system to enhance risk prevention and control capabilities[122] - The company has maintained a strict insider information management system, ensuring no leakage incidents occurred during the reporting period, thus guaranteeing the fairness and transparency of information disclosure[138] - The company has not reported any significant risks or dissenting opinions from the supervisory board during the reporting period[169] - The company has not received any non-standard audit opinions from its accounting firm[198] - The company has proposed to appoint new independent directors and board members, reflecting ongoing governance improvements[166][167] Social Responsibility and Environmental Impact - The company actively engages in social responsibility initiatives, including free health check-ups and community service activities[192] - A total of 30 public welfare clinics and 6 health lectures were organized by the company during the reporting period[193] - The company is not classified as a key pollutant discharge unit and has not faced any administrative penalties related to environmental issues[187] - The company has not implemented any carbon reduction measures during the reporting period[189] Future Outlook - The company aims to achieve a revenue target of 11.036 billion yuan and a net profit of 320 million yuan for 2024[114] - The company plans to enhance its pharmaceutical wholesale business by improving supplier management and expanding into private medical markets[115] - The retail business will focus on optimizing product structure and increasing the sales proportion of non-pharmaceutical products to boost gross margin[116] - The company will develop a comprehensive treatment system for kidney diseases, integrating blood purification and rehabilitation services[117] - The company is committed to digital transformation to enhance data analysis capabilities and provide more precise value-added services[120]

哈药集团人民同泰医药股份有限公司 董事会审计委员会 2023 年度履职报告 根据《上市公司治理准则》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第 1 号—规范运作》和《公司章 程》、公司《董事会审计委员会工作细则》等有关规定，公司董事会 审计委员会本着恪尽职守、勤勉尽责的原则，积极开展工作，发挥审 计委员会的监督、评估、核查作用，认真履行审计监督职责。现将公 司董事会审计委员会 2023 年度的履职情况汇报如下： 一、 审计委员会基本情况 公司董事会审计委员会由三名委员组成，鉴于公司董事、审计委 员会委员刘波先生及独立董事、审计委员会委员哈书菊女士辞职，经 公司 2023 年 12 月 26 日召开的第十届董事会第十次会议审议，选举 独立董事韩东平女士、董事尹世炜先生、独立董事郭丹女士共同组成 公司第十届董事会审计委员会，其中审计委员会主任委员由具有专业 会计资格的独立董事韩东平女士担任。 二、审计委员会 2023 年度会议召开情况 报告期内，公司董事会审计委员会共召开了 6 次会议，全体委员 均亲自出席了会议，具体情况如下： | 会议 | 时间 | | | | | 审议事项 | | ...

哈药集团人民同泰医药股份有限公司 独立董事 2023 年度述职报告 作为哈药集团人民同泰医药股份有限公司（以下简称"公司"） 的独立董事,2023 年度我严格按照《公司法》《证券法》《上市公司独 立董事管理办法》《上市公司治理准则》《公司章程》及《独立董事制 度》等有关规定，忠实、勤勉、诚信地履行独立董事的职责,及时了 解公司运营情况，积极参加相关会议，认真审议各项议案，独立客观 地发表意见，审慎行使表决权，促进公司规范运作。依法维护公司利 益及全体股东特别是中小股东的合法权益。现将 2023 年度独立董事 的履职情况汇报如下： 一、独立董事情况 （一）独立董事的基本情况 武滨：1960 年生，研究生，高级咨询师，执业药师。曾任山西 省医药公司企业管理科副科长，山西省医药管理局商业处副处长，山 西省药材公司副经理，山西省医药集团有限公司经济运行部部长、总 经理助理；中国医药商业协会常务副会长；现任中国医药企业管理协 会专家委员会委员、老百姓大药房连锁股份有限公司董事、亚宝药业 集团股份有限公司董事、山东科源制药股份有限公司董事、德展大健 康股份有限公司独立董事、浙江维康药业股份有限公司独立董事、山 西振东制药 ...

哈药集团人民同泰医药股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 为进一步建立健全哈药集团人民同泰医药股份有限公司 （以下简称"公司"）董事（不包括独立董事）及高级管理人员的考 核和薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司 法》《上市公司治理准则》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《哈药集团人民同泰医药股份有限公司公司章 程》（以下简称《公司章程》）及有关规定，公司特设立董事会薪酬 与考核委员会，并制定本工作细则。 第二条 董事会薪酬与考核委员会是董事会按照股东大会决议设 立的专门工作机构，主要负责制定公司董事及高级管理人员的考核标 准并进行考核；负责制定、审查公司董事及高级管理人员的薪酬政策 与方案，对董事会负责。 第三条 本工作细则所称董事是指在本公司支取薪酬的董事；高 级管理人员是指董事会聘任的总经理、副总经理、董事会秘书、财务 负责人及董事会认定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由 3 名董事组成，其中独立董事 2 名。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董 1 事或者全体董事的三分 ...

哈药集团人民同泰医药股份有限公司 董事会提名委员会工作细则 第一章 总 则 第一条 为规范哈药集团人民同泰医药股份有限公司(以下简称 "公司")高级管理人员的产生，优化董事会组成，完善公司治理结 构，根据《中华人民共和国公司法》《上市公司治理准则》《上海证 券交易所上市公司自律监管指引第 1 号——规范运作》《哈药集团人 民同泰医药股份有限公司公司章程》（以下简称《公司章程》）及有 关规定，公司特设立董事会提名委员会，并制定本工作细则。 第二条 董事会提名委员会是董事会按照股东大会决议设立的专 门工作机构，主要负责对公司董事和高级管理人员的人选、选择标 准和程序进行研究并提出建议。 第三条 本细则所称董事是指在本公司担任董事长、董事职务的 人员，高级管理人员是指董事会聘任的总经理、副总经理、董事会 秘书、财务负责人及由董事会认定的其他高级管理人员。 第二章 人员组成 第四条 提名委员会成员由 3 名董事组成，其中独立董事 2 名。 第五条 提名委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一提名，并由董事会选举产生。 第六条 提名委员会设主任委员 1 名，由独立董事委员担任，负 1 责主持委员 ...

哈药集团人民同泰医药股份有限公司 董事会审计委员会工作细则 第一章 总 则 第一条 为强化董事会决策功能，做到事前审计、专业审计，确 保董事会对经理层的有效监督，完善公司治理结构，根据《中华人民 共和国公司法》《上市公司治理准则》《上海证券交易所上市公司自律 监管指引第 1 号——规范运作》《哈药集团人民同泰医药股份有限公 司公司章程》（以下简称《公司章程》）等有关规定，公司特设立董事 会审计委员会，并制定本工作细则。 第二条 董事会审计委员会是董事会按照股东大会决议设立的专 门工作机构，主要负责公司内、外部审计的沟通、监督和核查工作。 第二章 人员组成 第三条 审计委员会成员由 3 名董事组成，且应当为不在公司担 任高级管理人员的董事，其中独立董事应当过半数。 第四条 审计委员会委员由董事长、二分之一以上独立董事或者 全体董事的三分之一提名，并由董事会选举产生。 第五条 审计委员会设主任委员（召集人）1 名，由独立董事委 员担任，负责主持委员会工作；主任委员在委员内选举，并报请董事 会批准产生。主任委员须具备会计相关的专业经验。 第六条 审计委员会任期与董事会一致，委员任期届满，连选可 1 以连任。期间如有 ...

哈药集团人民同泰医药股份有限公司 第十届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 哈药集团人民同泰医药股份有限公司（以下简称"公司"）第十 届董事会第十一次会议通知于 2024 年 3 月 13 日以书面及电子邮件方 式向全体董事发出，会议于 2024 年 3 月 27 日在公司七楼会议室以现 场结合通讯方式召开。本次会议应出席董事7 人，实际出席董事7人， 会议由公司董事长朱卫东先生主持，公司监事和高级管理人员列席会 议。本次会议的召集、召开和表决程序符合《公司法》和《公司章程》 的规定。 二、董事会会议审议情况 经与会董事认真审议，本次会议以记名投票表决方式表决通过了 如下议案： (一)审议通过《2023 年度董事会工作报告》 表决结果：7 票同意，0 票反对，0 票弃权。 证券代码：600829 证券简称：人民同泰 公告编号：临 2024-001 (二)审议通过《2023 年年度报告及摘要》 本议案已经公司董事会审计委员会2024年第三次会议审议通 ...